WallStreetZenWallStreetZen

NYSE: NVO
Novo Nordisk (Ozempic) Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Novo Nordisk (Ozempic) revenue was $40.56B for the trailing 12 months ending Dec 31, 2024, with 14.3% growth year over year. Quarterly revenue for the quarter (Q4 2024) ending on Dec 31, 2024 was $12.0B, up 13.6% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, NVO annual revenue was $40.5B, with 17.7% growth year-over-year.

NVO past revenue growth

How has NVO's revenue growth performed historically?

Company
17.71%
Industry
437.31%
Market
20.27%
NVO's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
NVO's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
NVO's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

NVO revenue history

Current Revenue
$40.5B
Current Earnings
$14.1B
Current Profit Margin
34.8%
NVO's has demonstrated consistent long-term... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance

Be the first to know when NVO announces revenue.

NVO Revenue History By Year

NVO Yearly RevenueNVO RevenueNVO ChangeNVO Revenue Growth
2024-12-31$40.50B$6.09B+17.71%
2023-12-31$34.41B$8.91B+34.95%
2022-12-31$25.50B$4.16B+19.52%
2021-12-31$21.33B$522.51M+2.51%
2020-12-31$20.81B$2.60B+14.27%
2019-12-31$18.21B$1.06B+6.18%
2018-12-31$17.15B-$857.68M-4.76%
2017-12-31$18.01B$2.19B+13.83%
2016-12-31$15.82B-$1.40B-8.14%
2015-12-31$17.22B$2.91B+20.31%
2014-12-31$14.32B-$1.30B-8.35%
2013-12-31$15.62B$1.04B+7.11%
2012-12-31$14.58B$2.18B+17.60%
2011-12-31$12.40B$1.04B+9.16%
2010-12-31$11.36B$1.81B+18.99%
2009-12-31$9.55B$1.03B+12.13%
2008-12-31$8.51B$695.70M+8.90%
2007-12-31$7.82B$577.20M+7.97%
2006-12-31$7.24B$871.87M+13.69%
2005-12-31$6.37B$861.08M+15.63%
2004-12-31$5.51B$1.12B+25.51%
2003-12-31$4.39B$886.67M+25.32%
2002-12-31$3.50B$153.52M+4.58%
2001-12-31$3.35B$417.61M+14.25%
2000-12-31$2.93BN/AN/A

1 of 2

Novo Nordisk (Ozempic) Revenue FAQ

What was NVO's revenue last quarter?

On Invalid Date, Novo Nordisk (Ozempic) (NYSE: NVO) reported Q4 2024 revenue of $11.95 billion up 22.47% year over year. In the same quarter last year, Novo Nordisk (Ozempic)'s revenue was $9.76 billion.

What was Novo Nordisk (Ozempic)'s revenue in 2024?

Novo Nordisk (Ozempic)'s annual revenue for the twelve months ending Dec 31, 2024 was $40.50 billion, a 17.71% increase year over year.

How much does Novo Nordisk (Ozempic) make in a day?

Based on Novo Nordisk (Ozempic) annual revenue for the past five years, NVO makes an average of $78,111,449.33 per day.

What was Novo Nordisk (Ozempic)'s annual revenue growth in the past year?

As of Q2 2025, Novo Nordisk (Ozempic)'s revenue has grown 17.71% year over year. This is 419.6 percentage points lower than the US Biotechnology industry revenue growth rate of 437.31%. Novo Nordisk (Ozempic)'s revenue in the past year totaled $40.56 billion.

How much does Novo Nordisk (Ozempic) make in a year?

Novo Nordisk (Ozempic)'s revenue by year for the past five years is:
  • Novo Nordisk (Ozempic)'s revenue for the twelve months ending Dec 31, 2024 was $40.50 billion, a 17.71% increase year over year.
  • Novo Nordisk (Ozempic)'s annual revenue for Dec 31, 2023 was $34.41 billion, a 34.95% increase from 2022.
  • Novo Nordisk (Ozempic)'s annual revenue for 2022 was $25.50 billion, a 19.52% increase from 2021.
  • Novo Nordisk (Ozempic)'s annual revenue for 2021 was $21.33 billion, a 2.51% increase from 2020.
  • Novo Nordisk (Ozempic)'s annual revenue for 2020 was $20.81 billion, a 14.27% increase from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.